Dr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care

Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the treatment landscape is rapidly evolving.In this in-depth discussion from ASCO 2026, Dr. Megan Kruse, Dr. Ryan Rader, and Dr. Praveen Vikas explore the latest advances in first-line treatment for metastatic TNBC, including the recently approved datopotamab deruxtecan and the growing role of sacituzumab govitecan.The panel reviews key findings from the TROPION-Breast02 and ASCENT-03 trials, discusses overall survival and progression-free survival outcomes, compares toxicity profiles, and shares practical guidance on selecting between ADC options in real-world clinical practice.Topics discussed include:• TROPION-Breast02 and Dato-DXd approval• ASCENT-03 and sacituzumab govitecan data• First-line treatment selection in metastatic TNBC• PD-L1 positive vs PD-L1 negative disease• ADC sequencing challenges• Managing ocular toxicity, stomatitis, and ILD• Quality-of-life considerations• Germline BRCA testing and PARP inhibitors• Patient-centered treatment decision-making• Future directions in metastatic triple-negative breast cancerAs treatment options continue to expand, clinicians face increasingly complex decisions about sequencing, toxicity management, and delivering the most effective therapy early in the disease course.Subscribe for more expert oncology discussions, ASCO 2026 highlights, and breast cancer treatment updates.